JOINT PAIN INJECTIONS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On January 17, 2024, Enlivex Therapeutics Ltd., a biotechnology company, announced that the Israeli Ministry of Health (IMOH) had authorized the initiation of a company-sponsored multi-country, double-blind, randomized, placebo-controlled Phase I/II trial to evaluate the efficacy, safety, and tolerability of Allocetra following injections into the target knee joint of up to 160 moderately to severely symptomatic osteoarthritis patients
• In October 2021, SEIKAGAKU CORPORATION, a biopharmaceutical company, announced the launch of HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp, a biotechnology company.
• In May 2021, Ono Pharmaceutical Co., Ltd., a pharmaceutical company, and SEIKAGAKU CORPORATION, a biopharmaceutical company, announced that they had launched JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; “JOYCLU”), a joint function improvement agent, for which SEIKAGAKU CORPORATION received the manufacturing and marketing approval in Japan in March 2021
• In June 2020, Bioventus Inc., a biopharmaceutical company, announced that it had signed a distribution agreement with Bazis NN, a Russia-based medical device and equipment distributor, as its authorized distributor for DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment, for the marketing and sale of orthopedic solutions in Russia 
• In January 2020, TRB Chemedica International SA, a pharmaceutical company, announced the results of a French multicenter, randomized, double-blind, controlled, non-inferiority study involving 292 patients with knee osteoarthritis, whose aim was to compare a single injection of Ostenil Plus (non-chemically modified 2% sodium hyaluronate) with a single injection of 0.8% hylan G‑F 20 (Synvisc‑One)